Marker molecule for predicting sensitivity of patient to preoperative chemoradiotherapy and surgical mesorectal resection and derivative product of marker molecule

A technique of radiotherapy, chemotherapy and resection, applied in a specific field, can solve problems such as unpredictable sensitivity and achieve good diagnostic efficiency

CN113846164AInactive Publication Date: 2021-12-28QINGDAO MEDINTELL BIOMEDICAL CO LTD
0 Cites 3 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
Publication Date
2021-12-28
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention discloses a marker molecule for predicting the sensitivity of a patient to preoperative chemoradiotherapy and surgical mesorectal resection and a derivative product of the marker molecule. The marker molecule is PDGFRA, CTDP1 and / or AGR2; and verification shows that the marker molecule has good diagnostic efficiency for predicting the sensitivity or reactivity of a rectal cancer patient to surgery treatment, and can be widely applied to prediction of the sensitivity of the rectal cancer patient to surgery treatment. The invention further discloses a pharmaceutical composition for improving the sensitivity of the rectal patient to the preoperative chemoradiotherapy and surgical mesorectal resection.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The present invention belongs to the technical field of biomedicine. Specifically, the present invention relates to marker molecules and derivatives thereof for predicting the sensitivity of patients to preoperative chemoradiotherapy combined with total mesorectal resection. More specifically, the present invention relates to predicting the sensitivity of patients to Marker molecules PDGFRA, CTDP1, and / or AGR2, and their derivatives, that are sensitive to preoperative chemoradiotherapy combined with total mesorectal resection. Background technique

[0002] Rectal cancer is one of the most common malignant tumors of the digestive tract, which refers to the cancer between the dentate line and the rectosigmoid junction. Its incidence rate ranks third among malignant tumors in my country, and its mortality rate ranks fifth among malignant tumors in my country. It has the epidemiological characteristics of younger age of onset and higher incidence. Accordi...

Examples

Embodiment 2

[0097] Example 2 Verification of the diagnostic efficacy of genes PDGFRA, CTDP1, and AGR2 in predicting the sensitivity of rectal cancer patients to preoperative chemoradiotherapy combined with total mesorectal resection

[0098] 1. Experimental method

[0099] For the differentially expressed genes PDGFRA, CTDP1, and AGR2 screened in Example 1 between responders and non-responders, use the R package "pROC" (version 1.15.0) to perform receiver operating characteristic (ROC) analysis, calculate The area under the receiver operating characteristic curve (AUC) was used to evaluate the effect of genes PDGFRA, CTDP1, AGR2, PDGFRA+CTDP1, PDGFRA+AGR2, CTDP1+AGR2, and PDGFRA+CTDP1+AGR2 on the prediction of colorectal cancer patients in the training set and validation set, respectively. Accuracy of preoperative chemoradiotherapy combined with total mesorectal resection for treatment sensitivity, wherein the AUC value ranges from 0 to 1;

[0100] Among them, when judging the diagnostic...